Sibutramine-induced weight loss and weight maintenance lead to clinically relevant reductions in risk factors associated with the metabolic syndrome. Treatment with the drug decreases visceral fat, improves lipid levels, decreases glycosylated haemoglobin and decreases uric acid concentrations. Sibutramine is effective in achieving weight loss in patients with type 2 diabetes but weight loss occurs more slowly than in non-diabetic patients. The criteria for predicting response to treatment in uncomplicated patients may not be appropriate to those with type 2 diabetes. Furthermore, it is important to set realistic goals for weight loss in type 2 diabetes to avoid the risk of denying effective treatment to patients.
Introduction
The broader medical community currently views obesity in terms of its metabolic and cardiovascular consequences rather than as a disease in its own right. Any new intervention for obesity will be judged, therefore, on its ability to impact on metabolic risk factors. This paper discusses the evidence from clinical trials of the effect of sibutramine on these risk factors.
Weight loss in obese patients with co-morbidities
It is well known that it is difficult to achieve meaningful weight loss in overweight and obese patients with type 2 diabetes. These patients find it more difficult to lose weight than obese patients who do not have diabetes. For example, Wing et al reported a study involving 12 obese diabetic patients and their obese non-diabetic spouses who were treated together in a behavioural weight control programme. 1 The decline in body weight was more pronounced in the non-diabetic spouses.
An overview of results from sibutramine clinical studies (Table 1) confirms that weight loss is harder to achieve for patients with diabetes, but shows that treatment with sibutramine does produce significant weight loss in overweight=obese patients with co-morbidities.
In terms of identifying those patients who are likely to respond favourably to sibutramine therapy, in non-diabetic patients weight loss of 2 kg or more in the first month has been shown to be a good predictor of long-term response. As shown in Figure 1 , the situation differs in obese diabetic patients. As the response to sibutramine in obese diabetic patients is slower than in uncomplicated obesity, 38% of patients who went on to achieve >5% weight loss at one year failed to lose >2 kg in the first month of treatment. The corresponding figure in non-diabetics was only 6%. It is, therefore, important to set realistic goals for weight loss in patients with type 2 diabetes.
Three placebo-controlled studies have been carried out to evaluate the efficacy of sibutramine in patients with type 2 diabetes. One enrolled newly diagnosed patients who were treated for one year with sibutramine 15 mg or placebo. 2 The second study involved patients taking sulphonylureas who were treated for 6 months with sibutramine 15 mg (or 20 mg) or placebo. 3 The third study enrolled patients taking metformin who were treated for one year with sibutramine 15 mg (or 20 mg) or placebo. 4 All patients received behavioural advice on diet and exercise. Sibutramine-treated patients had a significantly greater reduction in weight (P < 0.001) than the control group in both newly diagnosed patients and those being actively treated with sulphonylureas or metformin. Addition of sibutramine to basal therapy achieved approximately 7% weight loss. These studies used a single daily dose of sibutramine of 15 mg, which is higher than the start dose usually used in patients with uncomplicated obesity and was chosen in the clinical trial programme to overcome the known difficulties of promoting weight loss in these patients. A meta-analysis of these studies shows that three times as many sibutraminetreated patients achieved 5 and 10% weight loss compared with controls ( Figure 2) . 5 This highlights the point that physicians and patients should not be discouraged if initial weight loss is low in overweight patients with type 2 diabetes.
The weight loss achieved with sibutramine in this patient population is comparable to that found to reduce the risk of progression to diabetes in at-risk obese patients in the recent Diabetes Prevention Program trial 6 and the Finnish Diabetes Prevention Study 7 ( Figure 3 ). The weight reduction observed with sibutramine in patients with diabetes should provide significant health benefits, although this hypothesis has not been confirmed in long-term studies.
In both of the diabetes prevention studies, weight loss was achieved with lifestyle intervention alone rather than lifestyle intervention combined with drug treatment. It is important to remember that intervention programmes involving behaviour modification require considerable reinforcement and that it is difficult to maintain the weight loss long-term using only lifestyle intervention.
Effect of sibutramine on visceral fat
Visceral (abdominal) obesity is thought to be responsible for many of the metabolic consequences of obesity, and waist circumference is recognized as a marker for this type of obesity. In the STORM study, 8 sibutramine reduced waist circumference in the first 6 months and this reduction was maintained over the 2 y study period (Figure 4) . In contrast, when treatment stopped at month 6 and patients were randomised to placebo, waist circumference increased, which reinforces the concept that obesity is a chronic disease requiring ongoing treatment. Metabolic benefits of sibutramine therapy GJ Krejs
Evidence from computed tomography scans confirmed that this reduction in waist circumference was associated with a reduction in visceral fat. Analysis of the type of fat lost in the first 6 months of the STORM study showed that the greatest loss occurred in the visceral compartment with reduction of 24% in abdominal visceral fat (P < 0.001 compared with baseline) and a reduction of 17% in subcutaneous fat (P < 0.001 compared with baseline). 9 This is especially important in patients with type 2 diabetes who typically have 20 -25% more visceral fat than non-diabetic patients. Sibutramine treatment was associated with reduced waist circumference in the three diabetic studies discussed above in which treatment was added to dietary or hypoglycaemic therapy (Abbott Laboratories, data on file).
Effect of sibutramine on lipid profile
Weight loss produced by sibutramine is associated with benefits in the lipid profile. Meta-analysis of sibutramine 10 mg studies lasting 12 months shows that, compared with the control group (receiving diet and exercise alone), sibutramine is associated with an increase in HDL cholesterol (P < 0.01), and a reduction in triglycerides (P < 0.05) (Abbott Laboratories, data on file).
Data from the STORM study show that there is also a decrease in VLDL cholesterol and that the lipid effects are maintained long term ( Figure 5) . 8 Similar lipid changes also occur with sibutramine treatment in patients with type 2 diabetes, leading to a significant decrease in the total cholesterol:HDL ratio 8 ( Figure 6 ).
Effect of sibutramine on glycaemia
Sibutramine-induced weight loss is associated with reduction in the glycosylated haemoglobin (HbA 1c ) level in patients with diabetes. A meta-analysis undertaken to review the effects of sibutramine-induced weight loss in patients with type 2 diabetes showed an overall 0.4% reduction in HbA 1c .
The reduction in HbA 1c was related to the degree of weight loss achieved. In patients who lost 10% of baseline body weight, the HbA 1c reduction was 0.7% (P < 0.003; Abbott Laboratories, data on file). This is a clinically important reduction since the UK Prospective Diabetes Study showed that a 1% decrease in HbA 1c was associated with a significant reduction in diabetes-related complications. 10 
Effect of sibutramine on uric acid
Although there is still debate on the significance of uric acid as a risk factor for cardiovascular disease, many physicians do consider elevated uric acid to be a component of the metabolic syndrome. There is clear evidence from clinical studies that sibutramine-induced weight loss significantly reduces plasma uric acid levels in proportion to the degree of weight loss. In patients who lose 5% body weight, plasma uric acid falls by 10%. In those who lose 10% body weight, plasma uric acid falls by 15 -20% (Abbott Laboratories, data on file).
Conclusion
Sibutramine produces significant weight loss in overweight=obese patients who have associated co-morbidities. Sibutramine-induced weight loss leads to significant reductions in a number of metabolic risk factors that contribute to the metabolic syndrome: it decreases visceral fat, decreases triglyceride levels, increases HDL cholesterol, decreases glycosylated haemoglobin and decreases uric acid concentration. In type 2 diabetes, three times as many patients on sibutramine achieved a 5 and 10% weight loss compared with controls. However, obese type 2 diabetic patients lose weight more slowly than non-diabetic obese patients. When assessing response to sibutramine treatment at one month, a >2 kg cut-off may, therefore, not be appropriate. It should be reconsidered or there is a risk of denying effective treatment to a large proportion of patients with type 2 diabetes.
If the metabolic benefits associated with sibutramine treatment are maintained long term, they would be expected to lead to a reduction in mortality.
